It is very important to diagnose psoriatic arthritis at an early stage in order to prevent irreversible joint damage and this can affect greatly the quality of living of the patient. Dermatologists are at an excellent seat to diagnose psoriatic arthritis at an early stage in the patients of psoriasis visiting dermatological Out Patient Department(OPD)  Comprehensive data of prevalence and morbidity are still lacking in the Indian subcontinent. It is perhaps underdiagnosed in Indian settings or may be confused with other Rheumatological diseases like Rheumatoid Arthritis and Osteoarthritis. To provide optimal therapy to all patients of Psoriasis Arthritis it is important to know the prevalence, clinical patterns, burden of disease, and economic considerations.

In this study we will analyse the Prevalence of PsA and clinical correlates in the patient population of Psoriasis.

Interviewer –administered Questionnaire (as enclosed) will be used to collect socio-demographic characters like age; religion; education; occupation; residence; relevant history of the disease including onset, duration, progression of Psoriasis, body part invoved aggravating and relieving and associated factors, family history and associated comorbidities; Koebner’s phenomenon; presence of nail Psoriasis; treatment of Psoriasis(steroid therapy). 

Patients will be screened for Psoriatic Arthritis using Early Arthritis for Psoriatic Patients (EARP ranging from 0 to 10 where score greater than equal to 3 is considered screening positive)

Severity of the Psoriasis will be assessed by Psoriasis Area and severity score(PASI score ranges from 0 to 72, mild 0 to 3, moderate 3 to 10, and severe >10) and Nail Psoriasis severity Index (NAPSI score ranges from 0 to 160). 

Quality of life of Patient with Psoriasis And Psoriatic Arthritis will be assessed using Dermatology Life Quality Index(DLQI ranges from 0 to 30 with score 10 or above indicating severe )  and The Indian version of Health Assessment Questionnaire (HAQ) 

Baseline investigations will be done from the Blood sample (a maximum of 10ml) collected from every patient like Complete Blood Count(CBC), Erythrocyte sedimentation Rate(ESR), C- reactive protein(CRP), Liver Function Test(LFT), Kidney function test(KFT), Lipid Profile, Rheumatoid Factor(RF), Random blood Sugar(RBS), Radiography for the affected  joints will performed. 5ml of blood sample collected from every patient will be stored at -80°C for future analysis of specific biomarkers for Psoriatic Arthritis. 

An informed consent will be taken from all the patients included in the study. 

SCREENING

All patients will be screened for Psoriatic Arthritis using Early Arthritis for Psoriatic Patients (EARP)

All the patients who will be screening positive will be referred to rheumatologist for confirmatory test

CONFIRMATION

Appropriate radiological investigations will be carried out. X rays will be reported by a Radiologist. The final Diagnosis and Classification of Psoriatic Arthritis will be made by the Rheuamatologist on the basis of Classification Criteria for psoriatic Arthritis (CASPAR).

ANALYSIS 

The estimated prevalence of Psoriatic Arthritis among Psoriasis patients will be determined. We will also evaluate any significant clinical correlation between the development of Psoriatic Arthritis in Psoriatic Patients and known patient and disease characteristics. We will also study the difference in the Quality of Life in Psoriatic patients with psoriatic Arthritis and those without it